A preparation of Levamisole-encasuplating PVP/PMMA microparticles and their efficacy study of drug delivery of Levamisole toward ovarian cancer cells

• Main Authors: Ying-Ting Yeh, 葉映廷
• Other Authors: Meng-Yi Bai
• Format: Others
• Language: zh-TW
• Published: 2017
• Online Access: http://ndltd.ncl.edu.tw/handle/90967795998168274049

碩士 === 國立臺灣科技大學 === 醫學工程研究所 === 105 === Levamisole is a kind of drug which is used to treat worm infections .Recently, there is a new research discovering that Levamisole can inhibit the growth of ovarian cancer cells. We want to study the cell toxicity of Levamisole to ovarian cancer cell lines SKOV-3 & CP70, and design a drug carrier composed of PVP and PMMA. We produced the drug carrier and encapsulated Levamisole by electrospray system. Through the observation of SEM, the particle size is falling between 1.0-1.5 µm. The abbreviation of this drug carrier is Leva/PVP/PMMA MPs. We could collect the particles by two methods including dry collection and suspension collection, and found porosity created on the surface of particles after being soaked in water 20 minutes. The encapsulation efficiency of Leva/PVP/PMMA MPs is 20%, and drug loading content is 0.1%. Freedrug of Levamisole released 50% of drugs in 1 hour and 90% of drugs in one day. Compared to freedrug, the rate of drug release of Leva/PVP/PMMA MP is much slower.It released 50% of drugs after 4 hours and 70% of drugs in one day. 5 mM freedrug of Levamisole reduced 60% cell viability toward SKOV-3 cell lines, and the cell toxicity of Leva/PVP/PMMA MPs is same as freedrug. 0.1 g/mL Leva/PVP/PMMA MPs could reduce 60% cell viability toward SKOV-3 cell lines. On the other hand, 5 mM freedrug of Levamisole could only reduce 30% cell viability toward CP70 cell lines, and 0.1 g/mL Leva/PVP/PMMA MPs didn’t have a significant cell toxicity toward CP70 cell lines.